Regional immunosuppression for corneal transplantation

失明给患者带来了巨大的身体、情感和经济上的限制和困难。角膜移植是一种被广泛接受的手术治疗由角膜混浊引起的视力障碍，角膜是眼睛前部的透明窗口。用于移植的角膜是在获得捐赠者家属的许可后，从最近去世的人身上取出的。不幸的是，很大比例的角膜移植失败，因为它们被认为是外来的，并且受到接受者的排斥。一旦角膜移植失败，它对光线就不再透明。许多新的干预措施正在开发，以减少角膜移植排斥反应的发生率，但目前还不确定这些究竟应该如何传递给患者。本应用程序中描述的研究旨在发现治疗药物和干预措施如何能够最好地靶向，以防止角膜移植排斥反应。克服不必要的免疫反应将使角膜移植的结果提高多达30%。

Blindness exerts major physical, emotional and economic constraints and hardship upon the sufferer. Corneal transplantation is a well-accepted surgical treatment for visual impairment caused by opacification of the cornea, the transparent window at the front of the eye. Corneas for transplantation are retrieved from people who have recently died, after permission has been sought from the donor's family. Unfortunately, a significant proportion of corneal transplants fail because they are recognized as foreign, and undergo rejection by the recipient. Once a corneal graft has failed, it is no longer transparent to light. A number of novel interventions are being developed to reduce the incidence of corneal graft rejection, but at present it is uncertain exactly how these should be delivered to the patient. The research described in this application is designed to discover how therapeutic agents and interventions can best be targeted, to prevent corneal graft rejection. Overcoming an unwanted immune response would improve the outcome of corneal transplantation by as much as thirty percent.